Ireland regulator reports manufacturing deficiency at Biocon’s Bengaluru plant
PTI, May 4, 2022, 10:09 AM IST
Image: Official website
Biotechnology major Biocon Biologics on Tuesday said Ireland’s health regulator has reported some deficiencies in the manufacturing process at the company’s plant in Bengaluru.
The Health Products Regulatory Authority (HPRA), Ireland, conducted a GMP (Good Manufacturing Practice) inspection of one of Biocon Biologics’ new monoclonal antibody drug substance manufacturing facilities in Biocon Park, Bengaluru, between March 28 and April 1, 2022, a Biocon Biologics spokesperson said in a regulatory filing.
“The inspection report contains no ‘critical’ observations and only one of the deficiencies is categorised as ‘major’ which is being addressed expeditiously in consultation with the regulatory agency,” the spokesperson added.
The facility will help the company address the additional requirements of products in the European Union market, the spokesperson noted.
Biocon Biologics is a subsidiary of Biocon Ltd.
Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.
Top News
Related Articles More
Baku climate talks: The ‘X’ factor that could determine future of Global South
Kidnapped for ransom in 1998, 26/11 survivor Gautam Adani faces biggest trial
Gautam Adani charged in US with USD 250 mn bribery, fraud
India’s GDP growth likely to slip at 6.5 pc, maintains 7 pc estimate for FY25: Icra
RBI cautions public about ‘deepfake’ video of governor being circulated on social media
MUST WATCH
Latest Additions
BGT Day 1: Bumrah leads India’s spectacular bowling comeback after batting no-show
Cal HC stays demolition of illegal constructions in Mandarmoni
Delhi LG praises CM Atishi, calls her ‘thousand times better than her predecessor’
Centre releases 15th Finance Commission grant for rural local bodies in Karnataka
Kharge confident of Cong and allies coming to power in Maharashtra, Jharkhand
Thanks for visiting Udayavani
You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.